Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01866
European Journal of Endocrinology, Vol 152, Issue 4, 611-617
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Santbrink, E. J P
Right arrow Articles by Fauser, B. C J M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Santbrink, E. J P
Right arrow Articles by Fauser, B. C J M

CLINICAL STUDY

Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment

Evert J P van Santbrink, Femke P Hohmann, Marinus J C Eijkemans1, Joop S E Laven and Bart C J M Fauser2

Division of Reproductive Medicine, Department of Obstetrics and Gynaecology and 1 Centre for Clinical Decision Sciences, Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands and 2 Department of Reproductive Medicine, University Medical Centre, Utrecht, The Netherlands

(Correspondence should be addressed to E J P van Santbrink, Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands; Email: e.vansantbrink{at}erasmusmc.nl)

Objective: To assess whether the addition of metformin to gonadotrophin ovulation induction in insulin-resistant, normogonadotrophic, anovulatory women alters ovarian responsiveness to exogenous FSH.

Design: Placebo-controlled double-blind assessment in an academic hospital.

Results: After a progestagen withdrawal bleeding, patients were randomised for either metformin (n = 11) or placebo (n = 9) treatment. In cases of absent ovulation, exogenous FSH was subsequently administered to induce ovulation. Only during metformin treatment did body mass index and androgen (androstenedione and testosterone) levels decrease, whereas FSH and LH levels increased significantly. In the metformin group, a single patient ovulated before the initiation of exogenous FSH. Significantly more monofollicular cycles and lower preovulatory oestradiol concentrations were observed in women receiving FSH with metformin compared with FSH alone.

Conclusions: Metformin co-treatment in a group of insulin-resistant, normogonadotrophic, anovulatory patients resulted in normalization of the endocrine profile and facilitated monofollicular development during the FSH induction of ovulation.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
E. Moll, F. van der Veen, and M. van Wely
The role of metformin in polycystic ovary syndrome: a systematic review
Hum. Reprod. Update, November 1, 2007; 13(6): 527 - 537.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.